Takeda Alliance Boosts Liver Disease Venture Ambys’s $140m Launch

 
• By Ian Haydock

Takeda is investing in newly launched serious liver disease company Ambys Medicines to support the advancement of the US venture’s platform and pipeline, in line with its core strategic therapeutic priorities.

Liver cancer, CT scan upper abdomen.
NEW VENTURE AMBYS EYES NOVEL APPROACHES TO LIVER DISEASE • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas